| *Sponsored
(Nasdaq: AMIX) Reaches Major Milestone In Key PoC Human Clinical Study (Low Float Profile)
AMIX Ran Approximately 77% Intraday Last Time It Topped My Watchlist! July 21st Dear Reader,
An innovative company in the medical device sector is drawing attention as it expands its breakthrough method for managing pain in cancer patients.
Having recently received authorization to extend a clinical trial program, the organization is now including a range of visceral cancers in its research, moving beyond its original emphasis on pain associated with pancreatic cancer.
Initial findings highlight notable reductions in pain for patients, along with lowered opioid consumption and improvements in daily living.
The company's technology, which integrates sophisticated nerve detection with precise ablation techniques, positions it to address critical gaps in pain treatment.
As clinical efforts broaden, the company's potential reach within the pain management field could grow significantly, making it a noteworthy Nasdaq profile to follow.
It also doesn't hurt that a low float of fewer than 3Mn shares could create heightened volatility and a pair of analyst targets are pointing to triple-digit potential upside.
Oh, yeah! I almost forgot to share... This isn't the first time I've brought this MedTech profile to your attention.
Previously alerted towards the end of last month, AMIX ran approx. 77% intraday from an open of $1.37 to a high of $2.43 on June 27th.
Listen. Take a second to consider this Nasdaq biotech profile for your watchlist:
Autonomix Medical, Inc. (Nasdaq: AMIX)
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated.
The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies.
And based on multiple potential breakout catalysts, (Nasdaq: AMIX) has taken over my watchlist's top spot. Check them out:
No. 1 - Volatility Potential Could Be Heightened Because Of AMIX's Low Float Structure.
No. 2 - Two Analyst Targets Suggest Significant Upside Potential (More Than Triple-Digit!)
No. 3 - First Patient Dosing Represents A Major Milestone As AMIX Looks To Double The Potential Addressable Market.
No. 4 - Could Chart Support Levels Be Strengthening?
But more on those in a second...
Company Breakdown - All About Autonomix Medical, Inc. (Nasdaq: AMIX)
Autonomix Medical, Inc. is pioneering a transformative approach to nerve-targeted treatments, leveraging proprietary transvascular, precision-guided technology to address unmet needs in neurological and pain management markets.
The company’s mission centers on “Sense, Treat, and Verify,” a paradigm that enables real-time, high-resolution mapping and ablation of overactive nerves, particularly those implicated in severe pain syndromes such as pancreatic cancer-related pain.
Technology and Intellectual Property
Autonomix has developed a first-in-class platform with an extensive intellectual property portfolio, boasting over 120 patents issued and pending.
Its proprietary technology features a miniaturized, application-specific integrated circuit (ASIC) microchip (1–2 mm in size), paired with a custom antenna array.
This system is designed for ultra-high sensitivity, capable of detecting and differentiating neural signals less than 5 microvolts—far below the detection threshold of current cardiac sensing technologies, which typically sense signals above 100 microvolts.
The close proximity of the sensory chip to the antenna allows for immediate, high-resolution signal capture directly at the source, enabling precise targeting and real-time feedback during procedures.
Clinical Achievements and Pipeline
Autonomix’s initial proof-of-concept (PoC 1) trial focused on the treatment of intractable pain associated with pancreatic cancer, a leading cause of morbidity and mortality with a high prevalence of severe, difficult-to-manage pain.
The PoC 1 study involved 20 subjects across one clinical site, with the majority of patients treated via femoral access. Results demonstrated statistically significant pain reduction, with 100% of femoral-access patients responding to treatment.
Notably, pain relief was observed as early as 24 hours post-procedure.
At the 4–6 week follow-up, responding patients experienced a mean pain reduction of 4.67 points (59.2%) on the Visual Analog Scale (VAS), which is considered clinically meaningful.
Furthermore, 100% of responders required zero opioid use at 7 days, and 73% remained opioid-free at 4–6 weeks, even as their disease progressed.
No device or procedure-related serious adverse events were reported, underscoring the safety and tolerability of the approach.
Market Opp. and Expansion
The company estimates a combined market opp. exceeding $100Bn across a wide spectrum of neurological and pain-related diseases. | 
No comments:
Post a Comment